Table 2

Summary of the SUSTAIN safety outcomes8 9 11 15–21

Trial (n)Doses and comparatorsDuration in weeksAE (%)Discontinuation due to AE (%)GI AE (%): severe, moderate, mildDiscontinuation due to GI AE (%)Severe or BG-confirmed hypoglycemia (%)
SUSTAIN 1 (n=388)13SC semaglutide 0.5 mg3064638:<1, 15, 304None
SC semaglutide 1.0 mg56538: 2, 13, 323
Placebo53215: 0, 4, 12<1
SUSTAIN 2 (n=1231)8SC semaglutide 0.5 mg5675844: 3, 14, 377NR
SC semaglutide 1.0 mg711040: 3, 12, 358
Sitagliptin 100 mg72324: 1, 5, 203
SUSTAIN 3 (n=809)9SC semaglutide 1.0 mg56759NRNRtwo events*
Exenatide ER 2 mg767
SUSTAIN 4 (n=1089)15SC semaglutide 0.5 mg30 weeks70641: 2, 10, 363NR
SC semaglutide 1.0 mg73743: 2, 14, 385
Insulin glargine65115: 1, 4, 120
SUSTAIN 5 (n=397)12SC semaglutide 0.5 mg30695NRNR8%
SC semaglutide 1.0 mg64611%
Placebo58<15%
SUSTAIN 6 (n=3297)11SC semaglutide 0.5 mg104901251NR23%
SC semaglutide 1.0 mg89155222%
Placebo9163622%
Placebo8983521%
SUSTAIN 7 (n=1201)16SC semaglutide 0.5 mg4068843: 3, 13, 3653%
Dulaglutide 0.75 mg62533: 1, 7, 2821%
SC semaglutide 1.0 mg691044: 2, 16, 3862%
Dulaglutide 1.5 mg74748: 3, 13, 4252%
SUSTAIN 8 (n=788)17SC semaglutide 1.0 mg5276104772%
Canagliflozin 300 mg7252811%
SUSTAIN 9 (n=302)14SC semaglutide 1.0 mg3069937: 1, 14, 31711%
Placebo60213: 0, 3, 1102%
SUSTAIN 10 (n=577)18SC semaglutide 1.0 mg307111447NR
Liraglutide 1.2 mg667384
  • *The two events of ‘Severe or BG-confirmed Hypoglycemia’ during SUSTAIN 3 were both in the SC semaglutide 1.0 mg group.

  • AE, adverse events; BG, blood glucose; ER, extended release; GI, gastrointestinal; NR, not recorded; SC, subcutaneous; SUSTAIN, Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes.